The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global CD31 Antibody Market Research Report 2024

Global CD31 Antibody Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1737865

No of Pages : 118

Ask Your Query
Synopsis
CD31 Antibody can be used in a variety of scientific applications, including western blotting, immunohistochemistry, immunocytochemistry, immunoprecipitation, and ELISA. These antibodies target CD31 in human, mouse, rat, rabbit and pig samples.
Global CD31 Antibody market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CD31 Antibody market research.
Growing patient base, launch of novel CD31 antibody drugs, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in CD31 antibody market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global CD31 Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
BosterBio
Bio-Rad
Bioss
Thermo Fisher Scientific
NSJ Bioreagents
R and D Systems
Abcam
BioLegend
GeneTex
Novus Biologicals
SouthernBiotech
LifeSpan BioSciences
Enzo Life Sciences
Bethyl Laboratories
Abbexa
ProSci
Proteintech
Synaptic Systems
BIOCARE MEDICAL
CUSABIO Technology
Absolute Antibody
EpiGentek
Biorbyt
Wuhan Fine Biotech
Sino Biological
Segment by Type
Monoclonal
Polyclonal
Segment by Application
Immunochemistry (IHC)
Immunofluorescence (IF)
Western Blot (WB)
Immunocytochemistry (ICC)
ELISA
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The CD31 Antibody report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index
1 CD31 Antibody Market Overview
1.1 Product Overview and Scope of CD31 Antibody
1.2 CD31 Antibody Segment by Type
1.2.1 Global CD31 Antibody Market Value Comparison by Type (2023-2029)
1.2.2 Monoclonal
1.2.3 Polyclonal
1.3 CD31 Antibody Segment by Application
1.3.1 Global CD31 Antibody Market Value by Application: (2023-2029)
1.3.2 Immunochemistry (IHC)
1.3.3 Immunofluorescence (IF)
1.3.4 Western Blot (WB)
1.3.5 Immunocytochemistry (ICC)
1.3.6 ELISA
1.3.7 Others
1.4 Global CD31 Antibody Market Size Estimates and Forecasts
1.4.1 Global CD31 Antibody Revenue 2018-2029
1.4.2 Global CD31 Antibody Sales 2018-2029
1.4.3 Global CD31 Antibody Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 CD31 Antibody Market Competition by Manufacturers
2.1 Global CD31 Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global CD31 Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global CD31 Antibody Average Price by Manufacturers (2018-2023)
2.4 Global CD31 Antibody Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of CD31 Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CD31 Antibody, Product Type & Application
2.7 CD31 Antibody Market Competitive Situation and Trends
2.7.1 CD31 Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CD31 Antibody Players Market Share by Revenue
2.7.3 Global CD31 Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CD31 Antibody Retrospective Market Scenario by Region
3.1 Global CD31 Antibody Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global CD31 Antibody Global CD31 Antibody Sales by Region: 2018-2029
3.2.1 Global CD31 Antibody Sales by Region: 2018-2023
3.2.2 Global CD31 Antibody Sales by Region: 2024-2029
3.3 Global CD31 Antibody Global CD31 Antibody Revenue by Region: 2018-2029
3.3.1 Global CD31 Antibody Revenue by Region: 2018-2023
3.3.2 Global CD31 Antibody Revenue by Region: 2024-2029
3.4 North America CD31 Antibody Market Facts & Figures by Country
3.4.1 North America CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America CD31 Antibody Sales by Country (2018-2029)
3.4.3 North America CD31 Antibody Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe CD31 Antibody Market Facts & Figures by Country
3.5.1 Europe CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe CD31 Antibody Sales by Country (2018-2029)
3.5.3 Europe CD31 Antibody Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CD31 Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific CD31 Antibody Sales by Country (2018-2029)
3.6.3 Asia Pacific CD31 Antibody Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America CD31 Antibody Market Facts & Figures by Country
3.7.1 Latin America CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America CD31 Antibody Sales by Country (2018-2029)
3.7.3 Latin America CD31 Antibody Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa CD31 Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa CD31 Antibody Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa CD31 Antibody Sales by Country (2018-2029)
3.8.3 Middle East and Africa CD31 Antibody Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global CD31 Antibody Sales by Type (2018-2029)
4.1.1 Global CD31 Antibody Sales by Type (2018-2023)
4.1.2 Global CD31 Antibody Sales by Type (2024-2029)
4.1.3 Global CD31 Antibody Sales Market Share by Type (2018-2029)
4.2 Global CD31 Antibody Revenue by Type (2018-2029)
4.2.1 Global CD31 Antibody Revenue by Type (2018-2023)
4.2.2 Global CD31 Antibody Revenue by Type (2024-2029)
4.2.3 Global CD31 Antibody Revenue Market Share by Type (2018-2029)
4.3 Global CD31 Antibody Price by Type (2018-2029)
5 Segment by Application
5.1 Global CD31 Antibody Sales by Application (2018-2029)
5.1.1 Global CD31 Antibody Sales by Application (2018-2023)
5.1.2 Global CD31 Antibody Sales by Application (2024-2029)
5.1.3 Global CD31 Antibody Sales Market Share by Application (2018-2029)
5.2 Global CD31 Antibody Revenue by Application (2018-2029)
5.2.1 Global CD31 Antibody Revenue by Application (2018-2023)
5.2.2 Global CD31 Antibody Revenue by Application (2024-2029)
5.2.3 Global CD31 Antibody Revenue Market Share by Application (2018-2029)
5.3 Global CD31 Antibody Price by Application (2018-2029)
6 Key Companies Profiled
6.1 BosterBio
6.1.1 BosterBio Corporation Information
6.1.2 BosterBio Description and Business Overview
6.1.3 BosterBio CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 BosterBio CD31 Antibody Product Portfolio
6.1.5 BosterBio Recent Developments/Updates
6.2 Bio-Rad
6.2.1 Bio-Rad Corporation Information
6.2.2 Bio-Rad Description and Business Overview
6.2.3 Bio-Rad CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bio-Rad CD31 Antibody Product Portfolio
6.2.5 Bio-Rad Recent Developments/Updates
6.3 Bioss
6.3.1 Bioss Corporation Information
6.3.2 Bioss Description and Business Overview
6.3.3 Bioss CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bioss CD31 Antibody Product Portfolio
6.3.5 Bioss Recent Developments/Updates
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific Corporation Information
6.4.2 Thermo Fisher Scientific Description and Business Overview
6.4.3 Thermo Fisher Scientific CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Thermo Fisher Scientific CD31 Antibody Product Portfolio
6.4.5 Thermo Fisher Scientific Recent Developments/Updates
6.5 NSJ Bioreagents
6.5.1 NSJ Bioreagents Corporation Information
6.5.2 NSJ Bioreagents Description and Business Overview
6.5.3 NSJ Bioreagents CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.5.4 NSJ Bioreagents CD31 Antibody Product Portfolio
6.5.5 NSJ Bioreagents Recent Developments/Updates
6.6 R and D Systems
6.6.1 R and D Systems Corporation Information
6.6.2 R and D Systems Description and Business Overview
6.6.3 R and D Systems CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.6.4 R and D Systems CD31 Antibody Product Portfolio
6.6.5 R and D Systems Recent Developments/Updates
6.7 Abcam
6.6.1 Abcam Corporation Information
6.6.2 Abcam Description and Business Overview
6.6.3 Abcam CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Abcam CD31 Antibody Product Portfolio
6.7.5 Abcam Recent Developments/Updates
6.8 BioLegend
6.8.1 BioLegend Corporation Information
6.8.2 BioLegend Description and Business Overview
6.8.3 BioLegend CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BioLegend CD31 Antibody Product Portfolio
6.8.5 BioLegend Recent Developments/Updates
6.9 GeneTex
6.9.1 GeneTex Corporation Information
6.9.2 GeneTex Description and Business Overview
6.9.3 GeneTex CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GeneTex CD31 Antibody Product Portfolio
6.9.5 GeneTex Recent Developments/Updates
6.10 Novus Biologicals
6.10.1 Novus Biologicals Corporation Information
6.10.2 Novus Biologicals Description and Business Overview
6.10.3 Novus Biologicals CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Novus Biologicals CD31 Antibody Product Portfolio
6.10.5 Novus Biologicals Recent Developments/Updates
6.11 SouthernBiotech
6.11.1 SouthernBiotech Corporation Information
6.11.2 SouthernBiotech CD31 Antibody Description and Business Overview
6.11.3 SouthernBiotech CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.11.4 SouthernBiotech CD31 Antibody Product Portfolio
6.11.5 SouthernBiotech Recent Developments/Updates
6.12 LifeSpan BioSciences
6.12.1 LifeSpan BioSciences Corporation Information
6.12.2 LifeSpan BioSciences CD31 Antibody Description and Business Overview
6.12.3 LifeSpan BioSciences CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.12.4 LifeSpan BioSciences CD31 Antibody Product Portfolio
6.12.5 LifeSpan BioSciences Recent Developments/Updates
6.13 Enzo Life Sciences
6.13.1 Enzo Life Sciences Corporation Information
6.13.2 Enzo Life Sciences CD31 Antibody Description and Business Overview
6.13.3 Enzo Life Sciences CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Enzo Life Sciences CD31 Antibody Product Portfolio
6.13.5 Enzo Life Sciences Recent Developments/Updates
6.14 Bethyl Laboratories
6.14.1 Bethyl Laboratories Corporation Information
6.14.2 Bethyl Laboratories CD31 Antibody Description and Business Overview
6.14.3 Bethyl Laboratories CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bethyl Laboratories CD31 Antibody Product Portfolio
6.14.5 Bethyl Laboratories Recent Developments/Updates
6.15 Abbexa
6.15.1 Abbexa Corporation Information
6.15.2 Abbexa CD31 Antibody Description and Business Overview
6.15.3 Abbexa CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Abbexa CD31 Antibody Product Portfolio
6.15.5 Abbexa Recent Developments/Updates
6.16 ProSci
6.16.1 ProSci Corporation Information
6.16.2 ProSci CD31 Antibody Description and Business Overview
6.16.3 ProSci CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.16.4 ProSci CD31 Antibody Product Portfolio
6.16.5 ProSci Recent Developments/Updates
6.17 Proteintech
6.17.1 Proteintech Corporation Information
6.17.2 Proteintech CD31 Antibody Description and Business Overview
6.17.3 Proteintech CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Proteintech CD31 Antibody Product Portfolio
6.17.5 Proteintech Recent Developments/Updates
6.18 Synaptic Systems
6.18.1 Synaptic Systems Corporation Information
6.18.2 Synaptic Systems CD31 Antibody Description and Business Overview
6.18.3 Synaptic Systems CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Synaptic Systems CD31 Antibody Product Portfolio
6.18.5 Synaptic Systems Recent Developments/Updates
6.19 BIOCARE MEDICAL
6.19.1 BIOCARE MEDICAL Corporation Information
6.19.2 BIOCARE MEDICAL CD31 Antibody Description and Business Overview
6.19.3 BIOCARE MEDICAL CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.19.4 BIOCARE MEDICAL CD31 Antibody Product Portfolio
6.19.5 BIOCARE MEDICAL Recent Developments/Updates
6.20 CUSABIO Technology
6.20.1 CUSABIO Technology Corporation Information
6.20.2 CUSABIO Technology CD31 Antibody Description and Business Overview
6.20.3 CUSABIO Technology CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.20.4 CUSABIO Technology CD31 Antibody Product Portfolio
6.20.5 CUSABIO Technology Recent Developments/Updates
6.21 Absolute Antibody
6.21.1 Absolute Antibody Corporation Information
6.21.2 Absolute Antibody CD31 Antibody Description and Business Overview
6.21.3 Absolute Antibody CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Absolute Antibody CD31 Antibody Product Portfolio
6.21.5 Absolute Antibody Recent Developments/Updates
6.22 EpiGentek
6.22.1 EpiGentek Corporation Information
6.22.2 EpiGentek CD31 Antibody Description and Business Overview
6.22.3 EpiGentek CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.22.4 EpiGentek CD31 Antibody Product Portfolio
6.22.5 EpiGentek Recent Developments/Updates
6.23 Biorbyt
6.23.1 Biorbyt Corporation Information
6.23.2 Biorbyt CD31 Antibody Description and Business Overview
6.23.3 Biorbyt CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Biorbyt CD31 Antibody Product Portfolio
6.23.5 Biorbyt Recent Developments/Updates
6.24 Wuhan Fine Biotech
6.24.1 Wuhan Fine Biotech Corporation Information
6.24.2 Wuhan Fine Biotech CD31 Antibody Description and Business Overview
6.24.3 Wuhan Fine Biotech CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Wuhan Fine Biotech CD31 Antibody Product Portfolio
6.24.5 Wuhan Fine Biotech Recent Developments/Updates
6.25 Sino Biological
6.25.1 Sino Biological Corporation Information
6.25.2 Sino Biological CD31 Antibody Description and Business Overview
6.25.3 Sino Biological CD31 Antibody Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Sino Biological CD31 Antibody Product Portfolio
6.25.5 Sino Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CD31 Antibody Industry Chain Analysis
7.2 CD31 Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CD31 Antibody Production Mode & Process
7.4 CD31 Antibody Sales and Marketing
7.4.1 CD31 Antibody Sales Channels
7.4.2 CD31 Antibody Distributors
7.5 CD31 Antibody Customers
8 CD31 Antibody Market Dynamics
8.1 CD31 Antibody Industry Trends
8.2 CD31 Antibody Market Drivers
8.3 CD31 Antibody Market Challenges
8.4 CD31 Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock